

# Paolo Castellucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6805221/publications.pdf>

Version: 2024-02-01

89  
papers

4,168  
citations

136740

32  
h-index

110170

64  
g-index

91  
all docs

91  
docs citations

91  
times ranked

3221  
citing authors

#	ARTICLE	IF	CITATIONS
1	Theranostics in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, 333-341.	0.4	3
2	High dose brachytherapy with non sealed <sup>188</sup> Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results.. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1511-1521.	3.3	9
3	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. Journal of Nuclear Medicine, 2021, 62, 675-678.	2.8	16
4	Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 596-604.	2.8	79
5	Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. Clinical and Translational Imaging, 2021, 9, 215-220.	1.1	5
6	Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of <sup>68</sup> Ga-PSMA-11 in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 716-722.	2.8	20
7	Prediction nomogram for <sup>68</sup> Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 136-146.	3.3	56
8	Invited Commentary: Prostate-specific Membrane Antigen PET Response Assessment—Has the Time Come?. Radiographics, 2020, 40, 1431-1433.	1.4	0
9	Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. Current Opinion in Urology, 2020, Publish Ahead of Print, 641-648.	0.9	5
10	Invited Commentary: Changing Landscape of Imaging in Recurrent Prostate Cancer. Radiographics, 2020, 40, 727-730.	1.4	2
11	Predictive accuracy and clinical benefit of a nomogram aimed to predict <sup>68</sup> Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA <math>\leq 1\text{ ng/ml}</math> external validation on a single institution database. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2100-2105.	3.3	20
12	Alternative and New Radiopharmaceutical Agents for Lung Cancer. Current Radiopharmaceuticals, 2020, 13, 185-194.	0.3	11
13	Negative <sup>11</sup> C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values $> 20\text{ ng/mL}$ . Nuclear Medicine Communications, 2020, 41, 1178-1182.	0.5	0
14	<sup>68</sup> Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA $\leq 0.5\text{ ng/ml}$ . Efficacy and impact on treatment strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 11-19.	3.3	96
15	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. World Journal of Urology, 2019, 37, 2607-2613.	1.2	18
16	Male Breast Cancer Detected by <sup>68</sup> Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. Clinical Genitourinary Cancer, 2019, 17, 154-156.	0.9	9
17	<sup>18</sup> F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study. Cancers, 2019, 11, 700.	1.7	23
18	Potential Prognostic Role of <sup>18</sup> F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study. Cancers, 2019, 11, 713.	1.7	10

#	ARTICLE	IF	CITATIONS
19	How does <sup>68</sup> Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?. <i>International Journal of Urology</i> , 2019, 26, 804-811.	0.5	21
20	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFR $\pm$ mutation in a metastatic GIST patient responding to imatinib. <i>Scientific Reports</i> , 2019, 9, 2172.	1.6	5
21	Single Subcutaneous Prostate Cancer Metastasis Detected by <sup>68</sup> Ga-PSMA PET/CT During Early Biochemical Relapse: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e356-e359.	0.9	4
22	Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders. <i>PET Clinics</i> , 2019, 14, 183-191.	1.5	6
23	<sup>68</sup> Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 31-39.	3.3	74
24	State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 18-30.	0.5	16
25	Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 7-18.	0.4	19
26	Incidental Detection of Basaloid Thymic Carcinoma With <sup>68</sup> Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e497-e499.	0.9	3
27	Comparison between the diagnostic accuracies of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. <i>Abdominal Radiology</i> , 2018, 43, 2391-2399.	1.0	23
28	Pictorial essay: normal variants, lesions, and pitfalls in <sup>68</sup> Ga-PSMA PET imaging of prostate cancer. <i>Clinical and Translational Imaging</i> , 2018, 6, 239-247.	1.1	3
29	The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2253-2255.	3.3	0
30	Imaging of Prostate Cancer Using <sup>11</sup> C-Choline PET/Computed Tomography. <i>Urologic Clinics of North America</i> , 2018, 45, 481-487.	0.8	12
31	Preoperative Staging With <sup>11</sup> C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 305-312.e1.	0.9	19
32	A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by <sup>68</sup> Ga-PSMA PET/CT. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e525-e527.	0.9	3
33	Imaging of Prostate Cancer Using <sup>11</sup> C-Choline PET/Computed Tomography. <i>PET Clinics</i> , 2017, 12, 137-143.	1.5	2
34	The role of <sup>18</sup> F-FDG PET/CT in the detection of osteosarcoma recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1712-1720.	3.3	31
35	Development of standardized image interpretation for <sup>68</sup> Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	3.3	91
36	Therapy assessment in prostate cancer using choline and PSMA PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 78-83.	3.3	31

#	ARTICLE	IF	CITATIONS
37	New aspects of molecular imaging in prostate cancer. <i>Methods</i> , 2017, 130, 36-41.	1.9	21
38	Molecular Imaging and Precision Medicine in Prostate Cancer. <i>PET Clinics</i> , 2017, 12, 83-92.	1.5	9
39	Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients. <i>Diagnostics</i> , 2017, 7, 56.	1.3	8
40	<sup>18</sup> F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study. <i>Journal of Thyroid Research</i> , 2017, 2017, 1-9.	0.5	2
41	<sup>18</sup> F-Fdg-PET-guided Planning and Re-Planning (Adaptive) Radiotherapy in Head and Neck Cancer: Current State of Art. <i>Anticancer Research</i> , 2017, 37, 6523-6532.	0.5	8
42	<sup>11</sup> C- or <sup>18</sup> F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 43S-48S.	2.8	42
43	Evaluation of Prostate Cancer with <sup>11</sup> C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 49S-54S.	2.8	25
44	PET imaging in prostate cancer, state of the art: a review of <sup>18</sup> F-choline and <sup>11</sup> C-choline PET/CT applications. <i>Clinical and Translational Imaging</i> , 2016, 4, 449-456.	1.1	1
45	PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2103-2104.	3.3	7
46	<sup>11</sup> C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1971-1979.	3.3	79
47	<sup>11</sup> C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 84-91.	3.3	77
48	PET/CT with <sup>11</sup> C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 55-69.	3.3	200
49	<sup>11</sup> C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, e265-e270.	0.7	39
50	Identifying sites of recurrence with choline-PET-CT imaging. <i>Nature Reviews Urology</i> , 2015, 12, 134-135.	1.9	9
51	<sup>68</sup> Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1284-1294.	3.3	234
52	<sup>11</sup> C-Choline PET/CT for Restaging of Bladder Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, e1-e5.	0.7	23
53	<sup>68</sup> Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e415-e417.	0.9	15
54	PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. <i>PET Clinics</i> , 2015, 10, 487-494.	1.5	5

#	ARTICLE	IF	CITATIONS
55	State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2015, 68, 354-70.	0.1	14
56	Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2222-2231.	3.3	86
57	11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 878-886.	3.3	54
58	Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging <sup>11</sup> C-Choline PET/CT Scan Before Salvage Radiation Therapy?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1424-1429.	2.8	118
59	11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 149-155.	3.3	49
60	11C-Choline PET/CT and PSA kinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 36-40.	3.3	42
61	11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT. <i>Clinical Nuclear Medicine</i> , 2013, 38, e279-e282.	0.7	14
62	The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <math>\leq 0.5</math> ng/mL. <i>Clinical Nuclear Medicine</i> , 2013, 38, e342-e345.	0.7	63
63	Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy. <i>Clinical Nuclear Medicine</i> , 2013, 38, e26-e32.	0.7	72
64	11C-Choline PET/CT and PSA kinetics. <i>Archive of Oncology</i> , 2012, 20, 81-83.	0.2	0
65	Synthesis of oncological [11C]radiopharmaceuticals for clinical PET. <i>Nuclear Medicine and Biology</i> , 2012, 39, 447-460.	0.3	24
66	Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. <i>European Journal of Radiology</i> , 2012, 81, e893-e896.	1.2	106
67	Clinical Indications of 11C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse. <i>Theranostics</i> , 2012, 2, 313-317.	4.6	27
68	Choline PET/CT for prostate cancer: Main clinical applications. <i>European Journal of Radiology</i> , 2011, 80, e50-e56.	1.2	55
69	Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer. <i>Nuclear Medicine Communications</i> , 2011, 32, 475-478.	0.5	7
70	Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>Eur Urol</i> 2011;59:572-83. <i>European Urology</i> , 2011, 60, e37-e38.	0.9	10
71	Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <math>< 1.5</math> Ång/ml?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 55-63.	3.3	166
72	Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1985-1989.	3.3	67

#	ARTICLE	IF	CITATIONS
73	Incidence of Increased <sup>68</sup> Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 886-890.	2.8	57
74	Imaging with <sup>11</sup> Carbon labelled PET tracers. <i>Nuclear Medicine Communications</i> , 2010, 31, 613-616.	0.5	3
75	<sup>68</sup> Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 722-727.	3.3	107
76	Imaging with non-FDG PET tracers: outlook for current clinical applications. <i>Insights Into Imaging</i> , 2010, 1, 373-385.	1.6	13
77	Role of <sup>11</sup> C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. <i>Annals of Nuclear Medicine</i> , 2010, 24, 485-492.	1.2	70
78	Management of Patients with Gastrointestinal Stromal Tumor in Clinical Practice in Italy: A Critical "Event Tree Model" Analysis of Decision-Making Processes and Outcomes. <i>Tumori</i> , 2010, 96, 219-228.	0.6	0
79	Reply: Influence of Trigger PSA and PSA Kinetics on <sup>11</sup> C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2010, 51, 499-500.	2.8	4
80	<sup>68</sup> Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 669-673.	2.8	227
81	<sup>11</sup> C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2009, 95, 382-384.	0.6	28
82	Influence of Trigger PSA and PSA Kinetics on <sup>11</sup> C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1394-1400.	2.8	230
83	Comparison between <sup>68</sup> Ga-DOTA-NOC and <sup>18</sup> F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1431-1438.	3.3	254
84	<sup>11</sup> C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms. <i>European Urology</i> , 2008, 54, 392-401.	0.9	232
85	PET/CT in Neuroendocrine Tumors. <i>PET Clinics</i> , 2008, 3, 197-205.	1.5	2
86	Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and <sup>11</sup> C-Choline PET/CT. <i>Radiology</i> , 2007, 244, 797-806.	3.6	193
87	Role of <sup>18</sup> F-dopa PET/CT imaging in the management of patients with <sup>111</sup> In-pentetreotide negative GEP tumours. <i>Nuclear Medicine Communications</i> , 2007, 28, 473-477.	0.5	45
88	Role of <sup>18</sup> F-FDG PET/CT in the Management of Multiple Myeloma. <i>Blood</i> , 2005, 106, 3492-3492.	0.6	0
89	Detection and localization of prostate cancer: correlation of ( <sup>11</sup> C)-choline PET/CT with histopathologic step-section analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1642-9.	2.8	178